Assessment of dose contribution to pelvic lymph nodes in patients undergoing brachytherapy for carcinoma cervix
Background: The inclusion of pelvic lymph node (PLN) metastasis in the FIGO staging system has impacted disease classification and patient survival. Brachytherapy is a key component in managing carcinoma cervix; however, the dose contribution of brachytherapy to PLNs remains unclear. Aims and Obj...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Manipal College of Medical Sciences, Pokhara
2024-12-01
|
| Series: | Asian Journal of Medical Sciences |
| Subjects: | |
| Online Access: | https://www.nepjol.info/index.php/AJMS/article/view/69957 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846140658789646336 |
|---|---|
| author | Deepak Sharma Amrut S Kadam Ramashish Kumar Raghavendra BK Srihari G Perpetua Shruthi A Varun Chandra |
| author_facet | Deepak Sharma Amrut S Kadam Ramashish Kumar Raghavendra BK Srihari G Perpetua Shruthi A Varun Chandra |
| author_sort | Deepak Sharma |
| collection | DOAJ |
| description | Background: The inclusion of pelvic lymph node (PLN) metastasis in the FIGO staging system has impacted disease classification and patient survival. Brachytherapy is a key component in managing carcinoma cervix; however, the dose contribution of brachytherapy to PLNs remains unclear.
Aims and Objectives: This study aims to quantify the dose contribution of high-dose rate (HDR) brachytherapy to individual pelvic nodal groups.
Materials and Methods: We included 40 biopsy-proven carcinoma cervix patients, stages IIA to IVA. All patients underwent external beam radiotherapy (EBRT) with concurrent cisplatin chemotherapy, followed by HDR brachytherapy, either intracavitary brachytherapy (ICBT) or interstitial brachytherapy (ISBT). A total dose of 21 Gy in 3 fractions (7 Gy per fraction) was prescribed to the high-risk clinical target volume.
Results: For ICBT, the mean absolute doses received by the external iliac, internal iliac, and obturator groups were 0.56 Gy, 1.02 Gy, and 1.22 Gy, corresponding to EQD2 (α/β=10) values of 0.49 Gy, 0.93 Gy, and 1.14 Gy, respectively. In the ISBT group, the mean absolute doses were 0.49 Gy, 0.86 Gy, and 1.11 Gy, with corresponding EQD2s of 0.43 Gy, 0.85 Gy, and 1.02 Gy.
Conclusion: PLNs received significant dose contributions from HDR brachytherapy in cervical cancer patients, providing valuable reference data for determining the EBRT boost dose in cases of enlarged PLNs. |
| format | Article |
| id | doaj-art-d541d2352be6422b92c9804d3dbcfc78 |
| institution | Kabale University |
| issn | 2467-9100 2091-0576 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Manipal College of Medical Sciences, Pokhara |
| record_format | Article |
| series | Asian Journal of Medical Sciences |
| spelling | doaj-art-d541d2352be6422b92c9804d3dbcfc782024-12-05T06:36:10ZengManipal College of Medical Sciences, PokharaAsian Journal of Medical Sciences2467-91002091-05762024-12-011512176180https://doi.org/10.3126/ajms.v15i12.69957Assessment of dose contribution to pelvic lymph nodes in patients undergoing brachytherapy for carcinoma cervixDeepak Sharma 0https://orcid.org/0009-0004-6971-616XAmrut S Kadam 1https://orcid.org/0000-0002-7835-5317Ramashish Kumar 2https://orcid.org/0009-0008-4568-4684Raghavendra BK 3https://orcid.org/0009-0006-8705-6489Srihari G 4https://orcid.org/0009-0005-8393-2210Perpetua Shruthi A 5https://orcid.org/0009-0003-0819-0574Varun Chandra 6https://orcid.org/0009-0004-2601-3368Senior Resident, Department of Radiation Oncology, Lady Hardinge Medical College, New Delhi, India Professor, Department of Radiation Oncology, Victoria Hospital, Bengaluru Medical College and Research Institute, Karnataka, India Senior Resident, Department of Radiation Oncology, Lady Hardinge Medical College, New Delhi, India Senior Resident, Department of Radiation Oncology, Hassan Institute of Medical Sciences, Sri Chamarajendra District Hospital, Hassan, Karnataka, India Senior Resident, Department of Radiation Oncology, Karnataka Medical College and Research Institute, Hubballi (KMC-RI, Hubballi), Karnataka, India Registrar, HCG Cancer Centre, KR Road, Bengaluru, Karnataka, India Junior Resident, Department of Radiation Oncology, Victoria Hospital, Bengaluru Medical College and Research Institute, Karnataka, India Background: The inclusion of pelvic lymph node (PLN) metastasis in the FIGO staging system has impacted disease classification and patient survival. Brachytherapy is a key component in managing carcinoma cervix; however, the dose contribution of brachytherapy to PLNs remains unclear. Aims and Objectives: This study aims to quantify the dose contribution of high-dose rate (HDR) brachytherapy to individual pelvic nodal groups. Materials and Methods: We included 40 biopsy-proven carcinoma cervix patients, stages IIA to IVA. All patients underwent external beam radiotherapy (EBRT) with concurrent cisplatin chemotherapy, followed by HDR brachytherapy, either intracavitary brachytherapy (ICBT) or interstitial brachytherapy (ISBT). A total dose of 21 Gy in 3 fractions (7 Gy per fraction) was prescribed to the high-risk clinical target volume. Results: For ICBT, the mean absolute doses received by the external iliac, internal iliac, and obturator groups were 0.56 Gy, 1.02 Gy, and 1.22 Gy, corresponding to EQD2 (α/β=10) values of 0.49 Gy, 0.93 Gy, and 1.14 Gy, respectively. In the ISBT group, the mean absolute doses were 0.49 Gy, 0.86 Gy, and 1.11 Gy, with corresponding EQD2s of 0.43 Gy, 0.85 Gy, and 1.02 Gy. Conclusion: PLNs received significant dose contributions from HDR brachytherapy in cervical cancer patients, providing valuable reference data for determining the EBRT boost dose in cases of enlarged PLNs.https://www.nepjol.info/index.php/AJMS/article/view/69957brachytherapy; mean absolute dose; pelvic lymph nodes; carcinoma cervix |
| spellingShingle | Deepak Sharma Amrut S Kadam Ramashish Kumar Raghavendra BK Srihari G Perpetua Shruthi A Varun Chandra Assessment of dose contribution to pelvic lymph nodes in patients undergoing brachytherapy for carcinoma cervix Asian Journal of Medical Sciences brachytherapy; mean absolute dose; pelvic lymph nodes; carcinoma cervix |
| title | Assessment of dose contribution to pelvic lymph nodes in patients undergoing brachytherapy for carcinoma cervix |
| title_full | Assessment of dose contribution to pelvic lymph nodes in patients undergoing brachytherapy for carcinoma cervix |
| title_fullStr | Assessment of dose contribution to pelvic lymph nodes in patients undergoing brachytherapy for carcinoma cervix |
| title_full_unstemmed | Assessment of dose contribution to pelvic lymph nodes in patients undergoing brachytherapy for carcinoma cervix |
| title_short | Assessment of dose contribution to pelvic lymph nodes in patients undergoing brachytherapy for carcinoma cervix |
| title_sort | assessment of dose contribution to pelvic lymph nodes in patients undergoing brachytherapy for carcinoma cervix |
| topic | brachytherapy; mean absolute dose; pelvic lymph nodes; carcinoma cervix |
| url | https://www.nepjol.info/index.php/AJMS/article/view/69957 |
| work_keys_str_mv | AT deepaksharma assessmentofdosecontributiontopelviclymphnodesinpatientsundergoingbrachytherapyforcarcinomacervix AT amrutskadam assessmentofdosecontributiontopelviclymphnodesinpatientsundergoingbrachytherapyforcarcinomacervix AT ramashishkumar assessmentofdosecontributiontopelviclymphnodesinpatientsundergoingbrachytherapyforcarcinomacervix AT raghavendrabk assessmentofdosecontributiontopelviclymphnodesinpatientsundergoingbrachytherapyforcarcinomacervix AT sriharig assessmentofdosecontributiontopelviclymphnodesinpatientsundergoingbrachytherapyforcarcinomacervix AT perpetuashruthia assessmentofdosecontributiontopelviclymphnodesinpatientsundergoingbrachytherapyforcarcinomacervix AT varunchandra assessmentofdosecontributiontopelviclymphnodesinpatientsundergoingbrachytherapyforcarcinomacervix |